piotr_zarach
Member
- Joined
- Jan 30, 2014
- Messages
- 53
Efficacy and tolerability of potato juice in dyspeptic patients: a pilot study
"Normal" doses:
"Since about two-thirds of the patients benefited to some extent from the treatment, potato juice in its present formulation may be useful for self-treatment. However, placebo-controlled studies with a longer treatment period are needed to confirm this."
http://www.ncbi.nlm.nih.gov/pubmed/16360927
Very small doses:
"Three of the patients took 2 teaspoons/day of the concentrate, nine took 3 teaspoons/day and five consumed 3 tablespoons/day. Three outcome indicators were used. The GIS score, improvement in the worst rated GIS symptom (where more than 1 component had the same worst score before treatment, the 1 with the least improvement was chosen as the outcome variable) and self-rated efficacy. After 6 days, the GIS score had improved by 73 [+ or -] 32% (ITT, mean [+ or -] SD p < 0.001). The absolute GIS values improved from 12.8 [+ or -] 4.3 to 3.1 [+ or -] 3.7, the subjects' worst GIS symptom improved in 15 by a median score of 2 (Fig. 1). Of the 3 non-improvers, 2 were the patients who withdrew, and in the remaining one, of 6 GIS components which were rated as 2 at commencement of treatment, 5 had improved. The doses of the medication used did not correlate with either outcome variable, neither did age, nor sex, weight, BMI or the duration of acute or chronic symptoms. Fourteen patients improved their GIS by 60% or more and 10 patients rated the efficacy of the treatment as very good or good. Failure of the treatment was not observed in any of the patients. "
http://www.thefreelibrary.com/Further+e ... 0153402776
"Normal" doses:
"Since about two-thirds of the patients benefited to some extent from the treatment, potato juice in its present formulation may be useful for self-treatment. However, placebo-controlled studies with a longer treatment period are needed to confirm this."
http://www.ncbi.nlm.nih.gov/pubmed/16360927
Very small doses:
"Three of the patients took 2 teaspoons/day of the concentrate, nine took 3 teaspoons/day and five consumed 3 tablespoons/day. Three outcome indicators were used. The GIS score, improvement in the worst rated GIS symptom (where more than 1 component had the same worst score before treatment, the 1 with the least improvement was chosen as the outcome variable) and self-rated efficacy. After 6 days, the GIS score had improved by 73 [+ or -] 32% (ITT, mean [+ or -] SD p < 0.001). The absolute GIS values improved from 12.8 [+ or -] 4.3 to 3.1 [+ or -] 3.7, the subjects' worst GIS symptom improved in 15 by a median score of 2 (Fig. 1). Of the 3 non-improvers, 2 were the patients who withdrew, and in the remaining one, of 6 GIS components which were rated as 2 at commencement of treatment, 5 had improved. The doses of the medication used did not correlate with either outcome variable, neither did age, nor sex, weight, BMI or the duration of acute or chronic symptoms. Fourteen patients improved their GIS by 60% or more and 10 patients rated the efficacy of the treatment as very good or good. Failure of the treatment was not observed in any of the patients. "
http://www.thefreelibrary.com/Further+e ... 0153402776
